# ICANIC BRANDS COMPANY INC. (FORMERLY INTEGRATED CANNABIS COMPANY, INC.)

# CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTH PERIOD ENDED JANUARY 31, 2020

(Expressed in Canadian Dollars)

(Unaudited – prepared by management)

### **NOTICE TO READER**

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

# ICANIC BRANDS COMPANY INC. (FORMERLY INTEGRATED CANNABIS COMPANY, INC.)

**Condensed Consolidated Interim Statements of Financial Position** 

(Expressed in Canadian Dollars)

(Unaudited)

	January 31, 2020	July 31 2019	
	(Unaudited)	(Audited	
AS AT:	\$	(	
ASSETS			
Current assets			
Cash and cash equivalents	537,772	4,681,677	
Accounts receivable	1,150,162	582,420	
Government HST recoverable	70,776	48,954	
Prepaid expenses and deposits	1,792,905	156,479	
Inventory (note 14)	566,257	454,11	
Promissory note receivable (note 14)	1,456,624	1,447,26	
Loans receivable (note 7)	4,541,505	4,305,30	
	10,116,001	11,676,21	
Investments (note 17)	2		
Property and equipment (note 6)	3,512,384	2,704,188	
Brands and licenses (notes 13 and 14)	52,300,945	52,300,94	
,	, ,	, ,	
Total Assets	65,929,332	66,681,35°	
EQUITY AND LIABILITIES			
EQUITY AND LIABILITIES			
Current liabilities	574 157	610.56	
Current liabilities  Amounts payable and other liabilities (note 10)	574,157 111,328	619,56	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)	111,328		
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)	111,328 18,008	83,74	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)	111,328 18,008 12,500,000	83,748 12,500,000	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)	111,328 18,008	83,748 12,500,000	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)  Notes payable (note 13)	111,328 18,008 12,500,000	83,74 12,500,00	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)	111,328 18,008 12,500,000 13,203,493	619,564 83,748 12,500,000 13,203,312	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)  Notes payable (note 13)  Lease liability (note 15)  Total liabilities	111,328 18,008 12,500,000 13,203,493 281,717	83,744 12,500,000 13,203,312	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)  Notes payable (note 13)  Lease liability (note 15)  Total liabilities  Shareholders' Equity	111,328 18,008 12,500,000 13,203,493 281,717 13,485,210	83,744 12,500,000 13,203,312 13,203,312	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)  Notes payable (note 13)  Lease liability (note 15)  Total liabilities  Shareholders' Equity  Common share capital (note 11)	111,328 18,008 12,500,000 13,203,493 281,717 13,485,210	83,74 12,500,00 13,203,31 13,203,31 52,491,27	
Current liabilities  Amounts payable and other liabilities (note 10) Lease liability (note 15) Loan payable (note 10) Notes payable (note 13)  Lease liability (note 15)  Total liabilities  Shareholders' Equity Common share capital (note 11) Shares to be issued (note 14)	111,328 18,008 12,500,000 13,203,493 281,717 13,485,210 53,482,879 17,609,800	83,74 12,500,00 13,203,31 13,203,31 52,491,27 17,600,00	
Current liabilities  Amounts payable and other liabilities (note 10) Lease liability (note 15) Loan payable (note 10) Notes payable (note 13)  Lease liability (note 15)  Total liabilities  Shareholders' Equity Common share capital (note 11) Shares to be issued (note 14) Share subscriptions receivable	111,328 18,008 12,500,000 13,203,493 281,717 13,485,210 53,482,879 17,609,800 (45,663)	83,74 12,500,000 13,203,312 13,203,312 52,491,279 17,600,000 (95,286	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)  Notes payable (note 13)  Lease liability (note 15)  Total liabilities  Shareholders' Equity  Common share capital (note 11)  Shares to be issued (note 14)  Share subscriptions receivable  Reserves	111,328 18,008 12,500,000 13,203,493 281,717 13,485,210 53,482,879 17,609,800 (45,663) 5,388,188	83,74 12,500,00 13,203,31 13,203,31 52,491,27 17,600,00 (95,286 4,392,80	
Current liabilities  Amounts payable and other liabilities (note 10) Lease liability (note 15) Loan payable (note 10) Notes payable (note 13)  Lease liability (note 15)  Total liabilities  Shareholders' Equity Common share capital (note 11) Shares to be issued (note 14) Share subscriptions receivable	111,328 18,008 12,500,000 13,203,493 281,717 13,485,210 53,482,879 17,609,800 (45,663)	83,74 12,500,00 13,203,31 13,203,31 52,491,27 17,600,00 (95,286 4,392,80	
Current liabilities  Amounts payable and other liabilities (note 10)  Lease liability (note 15)  Loan payable (note 10)  Notes payable (note 13)  Lease liability (note 15)  Total liabilities  Shareholders' Equity  Common share capital (note 11)  Shares to be issued (note 14)  Share subscriptions receivable  Reserves	111,328 18,008 12,500,000 13,203,493 281,717 13,485,210 53,482,879 17,609,800 (45,663) 5,388,188	83,74 12,500,000 13,203,31	

Going concern (note 2)

Subsequent event (Note 18)

Approved on behalf of the Board of Directors March 30, 2020:

"Eugene Beukman" (signed)
Eugene Beukman, Director

"Nishal Kumar" (signed)

Nishal Kumar, Director

# ICANIC BRANDS COMPANY INC. (FORMERLY INTEGRATED CANNABIS COMPANY, INC.) Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars) (Unaudited)

(Unaudited)	For the three m ended Janu		For the six mo	
	2020	2019	2020	2019
Sales	1,780,211	91,380	3,607,494	92,482
Cost of sales	(1,489,836)	(30,756)	(2,789,230)	(30,756)
	290,375	60,624	818,264	(61,726)
Operating Expenses				
Advertising and promotion	149,286	159,823	967,767	220,530
Accretion	2,185	-	2,185	-
Bank charges	5,587	713	8,818	972
Depreciation	50,054	-	50,054	-
Filing and listing fees	7,357	6,018	34,486	21,828
Foreign exchange	45,042	-	45,042	-
Legal and professional fees	321,255	143,697	594,440	167,065
Management and consulting fees (note 10)	238,805	55,791	968,028	235,311
Office and general expenses	39,213	176,609	213,163	216,513
Stock-based compensation (note 11)	494,164	-	988,327	-
Transfer agent fees	21,551	2,015	27,511	6,143
Total operating expenses	(1,374,499)	(544,669)	(3,899,821)	(868,362)
Net loss before other items	(1,084,124)	(484,045)	(3,081,557)	(806,636)
Interest revenue	114	2,639)	1,232	2,732
	(1,084,010)	(481,406)	(3,080,325)	(803,904)
Net loss				
Foreign currency translation	8,685	(4,066)	7,058	24,075
Comprehensive loss	(1,075,325)	(485,472)	(3,087,383)	(779,829)
Basic and diluted net loss per share	(0.01)	(0.01)	(0.02)	(0.02)
Weighted average number of common shares outstanding	136,436,320	36,633,303	136,097,084	36,394,570

# ICANIC BRANDS COMPANY INC. (FORMERLY INTEGRATED CANNABIS COMPANY, INC.) Condensed Consolidated Interim Statements of Cash Flows (Expressed in Canadian Dollars) (Unaudited)

For the six months ended January 31,	2020 \$	2019
	Ψ	Ψ
Operating Activities		
Net loss for the period	(3,080,325)	(803,904)
Accretion expense	2,185	-
Depreciation	50,054	-
Foreign exchange	980	-
Consulting services	731,500	-
Foreign exchange	54,442	-
Share based compensation	988,327	-
Net changes in non-cash working capital		
Accounts receivable	(567,742)	(94,250)
Government HST recoverable	(21,822)	(4,4360
Prepaid expenses and deposits	(1,403,196)	-
Inventory	(112,142)	-
Accounts payable and accrued liabilities	(45,407)	105,943
Net cash used in operating activities	(3,403,146)	(796,647)
Investing activities		
Advances to Critical Mass Industries, LLC (note 12)	_	(762,720)
Investment in CA Brands (note 17)	(233,230)	(102,120)
Purchase of property and equipment	(457,810)	_
Rent repayments	(10,560)	_
Loans receivable	(300,000)	_
Net cash used in investing activities	(1,001,600)	(762,720)
Financing activities		
Share subscriptions received	49,623	
Obligation to issue shares	9,800	-
Exercise of warrants	260,100	228,835
Repayment of loans payable	(65,740)	-
Net cash provided by financing activities	253,783	228,835
	=,	
Net change in cash	(4,150,953)	(1,030,532)
Effect of foreign exchange on cash	7,058	24,075
Cash, beginning of period	4,681,677	1,719,569
Cash, end of period	537,772	713,112
Supplemental information		
Interest paid	\$ -	\$ -
Tax paid	\$ -	\$ -

# ICANIC BRANDS COMPANY INC. (FORMERLY INTEGRATED CANNABIS COMPANY, INC.) Condensed Consolidated Interim Statements of Changes in Equity (Expressed in Canadian Dollars) (Unaudited)

	Common S	Share (	Capital									
	Number of shares	Α	mount	Shares issu		Sha subscrip receiv	otions	foi cur	erve for reign rency slation	Reserve for share-based payments	Deficit	TOTAL
Balance at July 31, 2018	36,023,786	\$	15,170,422	\$	-	\$	_	\$	_	\$ 3,173,916	\$(16,335,050)	\$ 2,009,288
Exercise of warrants	670,522		228,835		-		-		-	-	-	228,835
Foreign currency translation	-		-		-		-		24,075	-	-	24,075
Loss for the period	-		-		-		-		-	-	(803,904)	(803,904)
Balance at January 31, 2019	36,694,308	\$	15,399,257	\$	-	\$		\$	24,075	\$ 3,173,916	\$(17,138,954)	\$ 1,458,294
Balance at July 31, 2019	134,209,393	\$	52,491,279	\$17,60	00,000	\$ (9	5,286)	\$	(43,443)	\$ 4,436,246	\$(20,910,757)	\$53,478,039
Exercise of warrants	693,594		260,100		· -	•	-		-	-	-	260,100
Shares for services	1,550,000		731,500		-		_		_	_	_	731,500
Share subscriptions received	-		-		9,800	4	49,623		_	-	-	59,423
Stock-based compensation	-		-		-		_		_	988,327	_	988,327
Foreign currency translation	-		_		-		_		7,058	-	-	7,058
Loss for the period	-				-		-		-		(3,080,325)	(3,080,325)
Balance at January 31, 2020	136,452,987	\$	53,482,879	\$17,60	9,800	\$ (4	5,663)	\$	(36,385)	\$ 5,424,573	\$(23,991,082)	\$52,444,122

# 1. Nature of Operations

Icanic Brands Company Inc. (Formerly Integrated Cannabis Company, Inc.) ("iCannaCo" or the "Company") was incorporated on September 15, 2011 under the laws of the province of British Columbia and is registered extra-provincially under the laws of Ontario. The Company was a mineral exploration company engaged in the acquisition and exploration of mineral resource properties in Canada. Prior to January 29, 2016, the Company was 85% owned by Winston Resources Inc. ("Winston" or the "Parent Company"). On January 18, 2016, Winston declared a special dividend to its shareholders by distributing all of its shareholding interest in the Company. The record date for the dividend is January 29, 2016. Winston no longer has any shareholder interest in the Company. The Company is a public company whose common shares are listed for trading on the Canadian Securities Exchange ("CSE") under the symbol "ICAN". The head office of the Company is located at Suite 810 - 789 West Pender Street, Vancouver, BC V6C 1H2, Canada.

During the period ended July 31, 2018, the Company completed the acquisition of all of the issued and outstanding shares of 1127466 B.C. Ltd., which holds a world-wide, exclusive license for X-Sprays a brand of state-of-the-art life enhancement products administered via an optimal oral spray delivery system (Note 3).

During the year ended July 31, 2019, the Company completed the acquisition of all of the issued and outstanding shares of 1200665 B.C. Ltd. (note 13), which intends to complete the acquisition of a Nevada cultivation manufacturing and real property interests of V6E Holdings LLC ("V6E") and Sullivan Park Capital LLC. ("Sullivan Park"), and also completed the acquisition of all of the issued and outstanding shares of Ganja Gold Inc. (note 14), which holds a California cannabis manufacturing interests.

# 2. Going Concern Assumption

These consolidated financial statements have been prepared on a going concern basis, which contemplates continuity of normal business activities and the realization of assets and discharge of liabilities in the normal course of business. As at January 31, 2020, the Company has yet to generate a positive net income and had an accumulated deficit of \$23,991,082 (July 31, 2019 - \$20,910,757). The Company is actively seeking additional sources of financing. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. Management is aware, in making its assessment, of uncertainties related to events or conditions that may cast significant doubt upon the entity's ability to continue as a going concern that these uncertainties are material and, therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Accordingly, they do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and therefore to realize its assets and discharge its liabilities and commitments in other than the normal course of business and at amounts different from those in the accompanying consolidated financial statements.

#### 3. Reverse Takeover

On October 25, 2017, the Company and 1127466 B.C. Ltd. ("1127466BC") signed a share exchange agreement whereby the Company would acquire all of the issued and outstanding shares of the 1127466BC which holds, through a wholly owned subsidiary, a world-wide, exclusive license for X-SPRAYS – a brand of life-enhancement products administered via an optimal oral spray delivery system. Pursuant to the terms of the agreement, Integrated Cannabis issued an aggregate of 16,500,000 common shares in the capital of the Company (the "payment shares"). Also, as part of the transaction, the Company also issued a finder's fee of 1,650,000 common shares in the capital of the Company.

# 3. Reverse Takeover (Continued)

For accounting purposes, the acquisition is considered to be outside the scope of IFRS 3 *Business Combinations* ("IFRS 3") since the Company, formerly known as CNRP Mining Inc., ("CNRP") was considered as a shell company whose activities, prior to the acquisition, were limited to the management of cash resources and maintenance of its reporting issuer status and did not constitute a business. The transaction is accounted for in accordance with IFRS 2 *Share-based Payment* ("IFRS 2") whereby 1127466BC is deemed to have issued shares in exchange for the net assets of the Company together with its reporting issuer status at the fair value of the consideration received by 1127466BC. The accounting for this transaction resulted in the following:

- (i) The financial statements of the consolidated entities are considered a continuation of the financial statements of 1127466BC.
- (ii) Since 1127466BC is deemed to be the acquirer for accounting purposes, its assets and liabilities are included in the financial statements at their historical carrying values.
- (iii) As part of the completion of the reverse acquisition with CNRP to facilitate the reporting issuer status of 1127466BC, the original shareholders of CNRP retained 17,857,786 common shares and 2,425,230 warrants of the Company. A finders' fee of 1,650,000 common shares were also issued to finders.

Since the share and share-based consideration allocated to the former shareholders of CNRP on closing the reverse acquisition is considered within the scope of IFRS 2, and the Company cannot identify specifically some or all of the goods or services received in return for the allocation of the shares, the value in excess of the net identifiable assets of CNRP acquired on closing was expensed in the statement of comprehensive loss as listing expense.

The share-based compensation of \$13,550,387 recorded as listing expense included the fair value of the 17,857,786 common shares retained by the former shareholders of CNRP and 1,650,000 common shares issued to the finders at \$0.76 per share, the fair value of 2,136,457 private placements warrants and 288,733 finders' warrants at a fair value of \$0.507 and \$0.381 per warrant respectively and the net assets acquired. The \$0.76 value for the shares was based on the most recent closing price prior to the reverse acquisition. The fair value of warrants were calculated using Black Scholes option pricing model using the assumptions at the time of the RTO of risk free interest rates of 1.29%, expected life of between 0.32 to 1.04 years, expected volatility of 100%, forfeiture rate of 0% and a dividend rate of 0%.

### 4. Statement of Compliance and Basis of Presentation

#### Statement of compliance

These condensed consolidated interim financial statements are prepared by the Company in accordance with International Accounting Standards 34 - Interim Financial Reporting of the International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretation Committee ("IFRIC"). The consolidated interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company's annual consolidated financial statements as at and for the period ended July 31, 2019.

These consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. Furthermore, these consolidated financial statements are presented in Canadian dollars which is the functional currency of the Company.

# 4. Statement of Compliance and Basis of Presentation (Continued)

#### Basis of consolidation

These consolidated financial statements include the financial statements of the Company and the entity controlled by the Company as follows:

Name	Date of acquisition
1127466 B.C. Ltd.	October 25, 2017
X-Sprays Industries Inc.	October 25, 2017
1200665 B.C. Ltd.	May 21, 2019
Ganja Gold Inc.	July 31, 2019

All inter-company transactions and balances have been eliminated in the consolidated financial statement presentation.

#### **Use of Estimates**

The preparation of these consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported expenses during the year. Actual results could differ from these estimates.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting period, that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to:

#### Critical accounting estimates

- i. Share-based payments and fair value adjustment to contingent liability are subject to estimation of the value of the award and warrants at the date of grant and measurement date using pricing models such as the Black-Scholes option valuation model. The option valuation model requires the input of highly subjective assumptions including the expected stock price volatility. Because the Company's stock options have characteristics significantly different from those of traded options and because the subjective input assumptions can materially affect the calculated fair value, such value is subject to measurement uncertainty.
- ii. The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. While income tax filings are subject to audits and reassessments, the Company has adequately provided for all income tax obligations. However, changes in facts and circumstances as a result of income tax audits, reassessments, jurisprudence and any new legislation may result in an increase or decrease in our provision for income taxes.
- iii. Management reviews the useful lives of depreciable assets including property and equipment and customer contracts at each reporting date based on the expected utility of the assets to the Company. Actual results, however, may vary due to technical obsolescence.

#### Critical accounting judgments

- i. The determination that the Company will continue as a going concern for the next year.
- ii. The revenue recognition of sale revenue.
- iii. The determination of related parties.

# 5. Significant Accounting Policies

# Changes in accounting policies

#### IFRS 16 - Leases

On January 13, 2016, the International Accounting Standards Board published a new standard, IFRS 16, Leases, eliminating the current dual accounting model for lessees, which distinguishes between onbalance sheet finance leases and off-balance sheet operating leases. Under the new standard, a lease becomes an on-balance sheet liability that attracts interest, together with a new right-of-use asset. In addition, lessees will recognize a front-loaded pattern of expense for most leases, even when cash rentals are constant. IFRS 16 is effective for reporting periods beginning on or after January 1, 2019, with early application permitted.

See notes 6 and 15 for the effect of the adoption of IFRS 16.

# 6. Property and Equipment

			Dia	ht of Iloo	
	<b>-</b> (1)		Rig	ht-of-Use	
	Building <sup>(1)</sup>	Equipment		Asset	TOTAL
00070					
COSTS					
Balance, July 31, 2018	\$ -	\$ -	\$	-	\$ -
Additions	2,704,188	-		-	2,704,188
Balance, July 31, 2019	2,704,188	-		-	2,704,188
Additions (note 15)	-	457,810		400,440	858,250
Foreign currency adjustments	-	· -		-	-
Balance, January 31, 2020	2,704,188	457,810		400,440	3,562,438
ACCUMULATED DEPRECIATION					
Balance, July 31, 2018 and 2019	_	_		_	_
Depreciation	_	_		50,054	50,054
Foreign currency adjustments	-	_		-	-
Balance, January 31, 2020	-	-		50,054	50,054
NET BOOK VALUE					
Balance, July 31, 2019	2,704,188	_		_	2,704,188
Balance, January 31, 2020	\$ 2,704,188	\$ 457,810	\$	350,386	\$ 3,512,284

(1) During the year ended July 31, 2019, the Company acquired 1200665BC (note 13) resulting in the acquisition of certain property and equipment with a carrying value of \$2,704,188. The business of 1200665BC through its investments in V6E and Sullivan Park has yet to commence as of July 31, 2019 and January 31, 2020. As a result, the Company did not amortize the property and equipment.

### 7. Loans Receivable

During the year ended July 31, 2019, the Company acquired 1200665BC (note 13) and Ganja Gold (note 14) resulting in the acquisition of certain loans receivable as follows:

Entity	Amount
1200665BC	\$ 4,241,505
Ganja Gold	63,798
Total	\$ 4,305,303

During the six months ended January 31, 2020, the Company advanced \$300,000 to 1200665BC. Loans receivable as at January 31, 2020 is as follows:

Entity	Amount
1200665BC	\$ 4,541,505
Ganja Gold	-
Total	\$ 4,541,505

The loans receivable acquired from 1200665BC are due from V6E and Sullivan Park as the closing conditions for the acquisitions of V6E and Sullivan Park by 1200665BC have not been met as of July 31, 2019 and January 31, 2020. The loans receivable acquired from Ganja Gold are due from the shareholders. The loans are unsecured, non-interest bearing and due on demand.

### 8. Financial Risk Management

### Classification of financial instruments

As at January 31, 2020	Financial assets -	Financial assets – amortized	Financial liabilities – amortized
	FVTPL	costs	costs
	\$	\$	\$
Cash	537,772	-	-
Accounts receivable	· -	1,150,162	-
Promissory note receivable	-	1,456,624	_
Loans receivable	-	4,541,505	-
Accounts payable and accrued liabilities	=	-	574,157
Loans payable	=	-	18,008
Notes payable	-	-	12,500,000

As at July 31, 2019	Financial assets - FVTPL	Financial assets – amortized costs	Financial liabilities – amortized costs
	\$	\$	\$
Cash	4,681,677	-	-
Accounts receivable	-	582,420	-
Promissory note receivable	-	1,447,268	-
Loans receivable	-	4,305,303	-
Accounts payable and accrued liabilities	-	-	619,564
Loans payable	-	-	83,748
Notes payable	-	-	12,500,000

The carrying values of the Company's financial instruments carried at amortized cost approximate fair values due to their short duration.

#### **Financial Risk Management Objectives and Policies**

The Company is exposed to various financial risks resulting from both its operations and its investments activities. The Company's management, with the Board of Directors oversight, manages financial risks. Where material, these risks will be reviewed and monitored by the Board of Directors. The Company does not enter into financial instrument agreements including derivative financial instruments for speculative purposes.

#### **Financial Risks**

The Company's main financial risk exposure and its financial risk management policies are as follows:

#### Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The credit risk is limited to the carrying value amount carried on the statement of financial position. Credit risk associated with the promissory note receivable (note 14) and loans receivable (note 7) arises from the possibility that the principal and/or interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationship. The Company is not currently exposed to any significant credit risk associated with its trade receivable.

#### **Market and Other Risks**

Market risk is the risk of uncertainty arising primarily from possible commodity market price movements and their impact on the future economic viability of the Company's projects and ability of the Company to raise capital. These market risks are evaluated by monitoring changes in key economic indicators and market information on an on-going basis and adjusting operating and exploration budgets accordingly.

#### **Liquidity Risk**

Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company manages its liquidity needs by carefully monitoring cash outflows due in day-to-day business.

Liquidity needs are monitored in various time bands, including 30-day, 180-day and 360-day lookout periods. As at January 31, 2020, the Company has a working capital deficiency of \$3,369,209 (2019 - \$3,087,492) and will require additional financing to meet its short term obligations.

# 9. Capital Management

The Company considers its capital to be comprised of shareholders' equity.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares. Although the Company has been successful at raising funds in the past through the issuance of capital stock, it is uncertain whether it will continue this method of financing due to the current difficult market conditions.

In order to facilitate management of its capital requirements, the Company prepares expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions.

There have been no changes to the Company's approach to capital management during the period.

# 10. Related Party Transactions and Disclosures

As of January 31, 2020, the amount due to related parties is \$18,008 (July 31, 2019 - \$18,009). This amount consists of amounts due to a former director of the Company. These amounts were made to provide working capital and are non-interest bearing and without fixed terms of repayment.

During the six months ended January 31, 2020, the Company paid/accrued management and consulting fees of \$55,000 (2018 - \$52,536) to companies controlled by the Chief Financial Officer of the Company. As at January 31, 2020, \$17,531 (July 31, 2018 - \$578) remained outstanding.

### 11. Share Capital

#### (i) Authorized capital

The Company's authorized share capital consists of:

- an unlimited number of common shares without par value; and
- an unlimited number of preferred shares issuable in series. No preferred shares are issued as of January 31, 2020.

#### (ii) Common shares

#### For the period ended January 31, 2019:

- a) During the month of September 2018, the Company issued 276,773 common shares upon exercise of warrants at \$0.40 per share.
- b) On November 6, 2018 and on June 12, 2019, the Company issued 143,749 common shares and 412,498 common shares upon exercise of warrants at \$0.30 per share respectively.
- c) On November 19, 2018 and on June 11, 2019, the Company issued 250,000 common shares and 143,749 common shares upon exercise of warrants at \$0.30 per share respectively.

# 11. Share Capital (Continued)

#### For the period ended January 31, 2020:

- d) The Company issued 609,677 common shares, valued at \$201,193, and 1,500,000 options exercisable at \$0.32 for a period of five years from the date of issuance to a consultant of the Company for services rendered. The common shares are subject to a voluntary escrow, and will be released quarterly starting 3 months from the date of the Agreement.
- e) On August 14, 2019, the Company issued 150,000 common shares, valued at \$76,500 to a consultant of the Company for services rendered.
- f) On August 16, 2019, the Company issued 1,250,000 common shares, valued at \$625,000 to a consultant of the Company for services rendered.
- g) In September 2019, the Company issued 693,594 common shares upon exercise of warrants at \$0.375 per share.
- h) On November 12, 2019, the Company issued 66,667 common shares with a fair value of \$30,000 to a consultant of the Company for services rendered.

On November 5, 2019, the Company announced that it, together with certain shareholders of the Company have entered into a voluntary pooling agreement. The voluntary pooling agreement will restrict the sale of approximately 26 million shares of the Company, representing approximately 20% of the issued and outstanding shares of the Company for six months from the date of the pooling agreement to May 1, 2020, bringing the total restricted shares outstanding to approximately 66 million shares, which collectively represents approximately 50% of the total outstanding shares of the Company.

# (iii) Stock options

The Company has a stock option plan in place under which the Board of Directors may grant options to acquire common shares of the Company to qualified directors, officers, employees and other service providers. The stock options vest according to the provisions of the individual option agreements approved by the directors' resolutions and have a maximum life of ten years. The plan allows for the issuance of up to 10% of the number of issued and outstanding common shares of the Company at any time on a non-diluted basis.

On July 31, 2019, the Company granted 4,100,000 stock options to consultants at an exercise price of \$0.33 per share expiring July 31, 2024. 1,650,000 options vest in 6 months and 2,450,000 options vest over 4 years. The fair value of these 4,100,000 stock options was determined to be \$1,796,211 using the Black Scholes Option Pricing Model using the assumptions at the time of grant of risk free interest rates of 1.47%, expected life of 5 years, expected volatility of 250%, forfeiture rate of 0% and a dividend rate of 0%. During the six month period ended January 31, 2020, the Company recognized share based compensation of \$988,327.

# 11. Share Capital (Continued)

The issued and outstanding options balance as at January 31, 2020 and July 31, 2019 is comprised as follows:

	Number of Options	Veighted erage Price
Balance November 30, 2017	-	\$ -
Options granted	3,600,000	\$ 0.40
Balance July 31, 2018	3,600,000	\$ 0.40
Options granted	9,600,000	\$ 0.33
Balance July 31, 2019 and January 31, 2020	13,200,000	\$ 0.35

As at January 31, 2020, 10,750,000 options remain outstanding with a weighted average price of \$0.35 and average life of 0.91 years.

As of January 31, 2020, the Company had share purchase options outstanding and exercisable to acquire common shares of the Company as follows:

	Exercise price	Number of options	Number of exercisable options
Expiry date	\$	. #	#
June 8, 2023	0.40	3,600,000	3,600,000
June 28, 2024	0.32	1,500,000	1,500,000
July 4, 2024	0.33	4,000,000	4,000,000
July 31, 2024	0.33	4,100,000	1,650,000
_		13,200,000	10,750,000

# (iv) Warrants

The issued and outstanding warrants balance as at January 31, 2020 and July 31, 2019 is comprised as follows:

	Exercise Price	Average Life	Expiry Date	Number of Warrants
Balance July 31, 2018	\$0.31	0.36		2,409,230
Private placements warrants	\$0.375	1.77	May 7, 2021	5,702,000
Finders' warrants	\$0.375	1.77	May 7, 2021	117,250
Private placements warrants	\$0.375	1.79	May 13, 2021	4,300,000
Finders' warrants	\$0.375	1.79	May 13, 2021	329,560
Private placements warrants	\$0.375	1.79	May 14, 2021	1,250,006
Finders' warrants exercised	\$0.40	=	September 26, 2018	(276,773)
Warrants exercised	\$0.30	-	June 13, 2019	(949,996)
Warrants expired	\$0.30	-	June 13, 2019	(1,182,461)
Balance July 31, 2019	\$0.375	1.78		11,698,816
Warrants exercised	\$0.375	-		(693,594)
Balance January 31, 2020	\$0.375	1.53		11,005,222

# 11. Share Capital (Continued)

# (v) Reserves

Reserves includes accumulated foreign currency translation adjustments and the accumulated fair value of share-based compensation and warrants transferred from share-based payment reserve and warrant reserve upon cancellation or expiry of the stock options and warrants.

On May 31, 2018, as a result of the RTO, 2,136,457 private placements warrants and 288,733 finders' warrants were considered issued to the former shareholders of CNRP at a fair value of \$1,082,312 and \$110,052 respectively. The total fair value of \$1,192,364 of warrants was recorded as reserve as part of the consideration issued for acquisition.

#### 12. Letter of Intent

In October 2018, the Company signed a Letter of Intent (the "LOI") to acquire all of the issued and outstanding securities of Critical Mass Industries, LLC ("CMI"), a Colorado-based cannabis leader operating successfully for nearly 10-years under the brands Good Meds and BOSM Labs. Integrated Cannabis has paid a non-refundable deposit of US\$250,000 upon signing the LOI. The Company paid a total of US\$450,000 during the year ended July 31, 2019. At closing, will pay an additional US\$2,400,000 and issue 2,300,000 Integrated Cannabis common shares to the shareholders of CMI in exchange for the securities being acquired. During the year ended July 31, 2019, the Company terminated the LOI to acquire all of the issued and outstanding securities of CMI and wrote-off the advances of \$597,310 to a carrying value of \$Nil.

#### 13. Acquisition of 1200665 B.C. Ltd.

On May 21, 2019, the Company entered into a share exchange agreement (the "BC Definitive Agreement") among the Company, 1200665 B.C. Ltd., a private British Columbia company ("1200665BC") and the shareholders of 1200665BC, pursuant to which, the Company will acquire all of the issued and outstanding shares of 1200665BC ('BC Transaction"). 1200665BC, through its interests in V6E and Sullivan Park, is the owner of a cannabis cultivation business and license and prospective owner of a cannabis manufacturing business and license in the state of Nevada.

In consideration for the BC Transaction and pursuant to the terms of the BC Definitive Agreement, the Company: (a) has issued an aggregate of 30,645,161 common shares of the Company pro rata to shareholders of 1200665BC on the closing of the BC Transaction (the "BC Closing Date"); (b) will pay \$5,019,900 in cash, payable within 120 days following the BC Closing Date; and (c) will pay up to an additional \$7,480,100 in cash, payable upon 1200665BC completing certain milestones after the BC Closing Date.

# 13. Acquisition of 1200665 B.C. Ltd. (Continued)

The purchase price allocation of 1200665BC's assets acquired and liabilities assumed is summarized below:

Purchase price:	Amount
Paid in shares	\$ 11,645,161
Payable in cash recorded as notes payable	12,500,000
Total purchase price	\$ 24,145,161
Assets acquired:	
Cash	\$ 468,669
Accounts receivable	1,301
Investments	2
Property and equipment (note 6)	2,704,188
Loans receivable (note 7)	2,740,373
Brands and licenses	18,333,221
Liabilities assumed:	
Accounts payable and other liabilities	27,641
Loans payable	74,952
Net assets acquired	\$ 24,145,161

### 14. Acquisition of Ganja Gold Inc.

On July 31, 2019, the Company entered into a share exchange agreement (the "California Definitive Agreement") among the Company, Ganja Gold Inc., a California company ("Ganja Gold") and the shareholders of Ganja Gold, pursuant to which, the Company will acquire all of the issued and outstanding shares of Ganja Gold ("California Transaction"). Ganja Gold is a State and municipally licensed cannabis manufacturing business.

In consideration for the California Transaction and pursuant to the terms of the California Definitive Agreement, the Company: (a) has issued and aggregate of 40,000,000 common shares of the Company (the "Payment Shares") pro rata to shareholders of Ganja Gold on the closing of the California Transaction (the "California Closing Date"); (b) will issue up to an additional 40,000,000 common shares upon Ganja Gold completing certain milestones after the Closing Date. See note 18. The Payment Shares are subject to a voluntary hold period of 12 months from the California Closing Date which expires July 31, 2020.

In connection with the California Transaction, the Company issued 3,200,000 common shares to an arm's length third party finder. The finder shares are subject to a statutory hold period of 4 months and a day from the California Closing Date which expires December 1, 2019.

# 14. Acquisition of Ganja Gold Inc.

The purchase price allocation of Ganja Gold's assets acquired and liabilities assumed is summarized below:

Purchase price:		<b>A</b> mount
Paid in shares	\$	17,600,000
Paid in shares – finder's fees		1,408,000
Payable in shares recorded as shares to be issued		17,600,000
Total purchase price	\$	36,608,000
Assets acquired:	_	
Cash	\$	449,100
Accounts receivable		537,419
Inventory		454,115
Deposit		131,480
Promissory note		1,447,268
Loans receivable		63,798
Brands and licenses		33,967,724
Liabilities assumed:		
Accounts payable and other liabilities		377,164
Loans payable		65,740
Net assets acquired	\$	36,608,000

### 15. Commitment

The Company, through its wholly owned subsidiary, Ganja Gold, has a lease commitment in California, USA for approximately 4,000 sq. ft. facility for cannabis manufacturing. Future payments for the facility are as follows:

Periods	Annual Rent (US Dollar)	
August 1, 2019 to July 31, 2020	\$	96,000
August 1, 2020 to July 31, 2021		96,000
August 1, 2021 to July 31, 2022		96,000
August 1, 2022 to July 31, 2023		96,000
Total	\$	384,000

On adoption of IFRS 16, Leases, the Company recognized the right-of-use asset (note 6), and a corresponding increase in a lease liability, in the amount of \$400,440 which represented the present value of future lease payments using a discount rate of 12%.

During the six months ended January 31, 2020, the Company recorded an accretion expense of \$2180 related to the lease liability.

# 16. Segmented Information

The assets and operations of the Company are located in Canada and the United States. The Company has one reportable business segments in the canadis sector.

	Canada	USA	TOTAL
Six month period ended	\$	\$	\$
Revenues	-	3,607,494	3,607,494
Total expenses	(3,072,197)	(3,584,928)	(6,657,125)
Net loss	(3,072,197)	22,566	(3,049,631)
As at January 31, 2020			
Current assets	4,667,387	5,448,614	10,116,001
Total assets	7,371,579	58,557,753	65,929,332
Total liabilities	350,546	13,134,664	13,485,210
As at July 31, 2019			
Current assets	8,146,235	3,529,981	11,676,216
Total assets	8,146,235	58,535,117	66,681,352
Total liabilities	262,198	12,941,115	13,203,313

#### 17. Other investments

On August 30, 2019, the Company announced it has entered into a term sheet (the "Term Sheet") to acquire Nevada based CannaAmerican Brands LLC ("CA Brands").

The term sheet contemplates the Company acquiring all of the issued and outstanding shares of CA Brands for \$4,000,000 to be satisfied through the issuance of common shares of the Company at a deemed price per share of \$0.45.

The Term Sheet sets out certain terms and conditions pursuant to which the proposed transaction will be completed. The proposed transaction remains subject to certain closing conditions including, without limitation, (a) the receipt by the Company of all necessary corporate and regulatory approval; (b) customary due diligence; (c) definitive agreements; (d) each party's representations and warranties in the share purchase agreement being true and correct in all aspects, and each party meeting its terms and conditions and completing its covenants and obligations as contained therein; and (e) all of the requisite municipal and State approvals. There can be no guarantees that the proposed transaction will be completed as contemplated at all. The Company may pay a finder's fee in relation to the proposed transaction in accordance with CSE policies.

The Company advanced \$233,230 to CA Brands during the period ended January 31, 2020.

### 18. Subsequent events

On February 5, 2020, the Company issued 40,000,000 common shares pursuant to the California Definitive Agreement with Ganga Gold.

On February 6, 2020, the Company entered into an amending agreement (the "Amending Agreement") with 1200665 B.C. Ltd. and settled \$12,500,000 of outstanding debt through the issuance of 40,322,580 common shares.